Harris Associates L P Bristol Myers Squibb CO Transaction History

Harris Associates L P

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $5.21 Million - $6.18 Million	-121,824 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $32.8 Million - $36.3 Million	-734,850 Reduced 85.78%	121,824 $5.53 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $288 Million - $344 Million	-6,385,692 Reduced 88.17%	856,674 $40.9 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $38.1 Million - $49.4 Million	-781,743 Reduced 9.74%	7,242,366 $376 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $21.5 Million - $24.2 Million	-388,967 Reduced 4.62%	8,024,109 $498 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $393 Million - $490 Million	7,772,870 Added 1214.12%	8,413,076 $466 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $8.89 Million - $10.2 Million	148,420 Added 30.18%	640,206 $40.5 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $5.99 Million - $6.53 Million	99,905 Added 25.49%	491,786 $30.1 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $21.6 Million - $25 Million	391,881	391,881 $25 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Harris Associates L P, based on Form 13F filings with the SEC.

Stay updated on Harris Associates L P with notifications on news.